BEIERSDORF SEES SALES AND PROFIT UP

12 April 1992

Profits at the north German drugs group Beiersdorf AG have incr-eased at an above-average rate in relation to good sales growth in 1991. The 1991 sales of the parent company rose 9.1% to 2.03 billion Deutschemarks ($1.2 billion), with net earnings up 10.3% to 107 million marks.

Sales improved in all business sectors. Domestic turnover rose 10.4% to 1.59 billion marks, while increased deliveries to subsidiaries abroad pushed up exports by 4.3% to 370 million marks. The company says that apart from sales growth, the other key factor in the profits picture was relatively low growth in material and personnel costs, together with higher earnings from the license business.

Group profits went up 25% last year to 147.2 million marks on sales up 13.8% to 4.49 billion marks. Improvements in the company's structure, especially in the subsidiaries, helped sales growth, with the addition of Juvena and Jobst adding 4.2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight